兰索拉唑与雷尼替丁治疗糜烂性食管炎的比较。多中心研究组。
A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
作者信息
Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose P A, Jennings D E
机构信息
Oklahoma Foundation for Digestive Research, University of Oklahoma Health Center, Oklahoma City 73104, USA.
出版信息
Aliment Pharmacol Ther. 1995 Feb;9(1):25-31. doi: 10.1111/j.1365-2036.1995.tb00347.x.
BACKGROUND
Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard dose of ranitidine in the treatment of patients with reflux oesophagitis.
METHODS
Two hundred and forty-seven patients with erosive oesophagitis were randomly assigned to 8 weeks of treatment with either 30 mg lansoprazole once daily or 150 mg ranitidine twice daily.
RESULTS
Two hundred and forty-two patients were included in the analysis. Lansoprazole (30 mg) daily, healed oesophagitis in 92.1% of patients after 8 weeks of treatment. This was significantly superior to 150 mg ranitidine b.d.s. which healed oesophagitis in 69.9% of patients (P < 0.001). Relief of reflux symptoms was superior with lansoprazole to that with ranitidine. Both lansoprazole and ranitidine were well tolerated with no serious drug-related adverse events noted.
CONCLUSION
Lansoprazole, 30 mg once daily, is highly effective and safe in the short-term treatment of erosive oesophagitis.
背景
兰索拉唑是一种新型质子泵抑制剂，可使胃酸分泌长期减少。本研究旨在比较兰索拉唑与标准剂量雷尼替丁治疗反流性食管炎患者的疗效。
方法
247例糜烂性食管炎患者被随机分配，分别接受为期8周的每日一次30毫克兰索拉唑治疗或每日两次150毫克雷尼替丁治疗。
结果
242例患者纳入分析。治疗8周后，每日服用30毫克兰索拉唑的患者中，92.1%的食管炎得到治愈。这显著优于每日两次服用150毫克雷尼替丁，后者使69.9%的患者食管炎得到治愈（P<0.001）。兰索拉唑缓解反流症状的效果优于雷尼替丁。兰索拉唑和雷尼替丁耐受性均良好，未观察到严重的药物相关不良事件。
结论
每日一次30毫克兰索拉唑在糜烂性食管炎的短期治疗中高效且安全。
Zotero 插件